| A Study of FVIII Gene Therapy for Hemophilia A (NCT05454774) | Institute of Hematology & Blood Diseases Hospital, China | 2022-07-19 |
| ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) (NCT05632380) | Institute of Hematology & Blood Diseases Hospital, China | 2022-07-14 |
| Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients (NCT05361057) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-29 |
| Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function (NCT05571332) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-28 |
| Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia (NCT05335226) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-06 |
| A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency (NCT05531279) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-05 |
| Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly (NCT05433922) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-01 |
| The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA (NCT05518331) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-01 |
| Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia (NCT05395507) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-01 |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia (NCT05356169) | Institute of Hematology & Blood Diseases Hospital, China | 2022-05-19 |
| GVM±R in Patients With Relapsed or Refractory Aggressive NHL (NCT05299164) | Institute of Hematology & Blood Diseases Hospital, China | 2022-05-15 |
| Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (NCT05294055) | Institute of Hematology & Blood Diseases Hospital, China | 2022-04-26 |
| Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (NCT05601466) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-26 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (NCT05287984) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-22 |
| Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (NCT05318963) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-14 |
| A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (NCT05292898) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-14 |
| Herombopag for Chemotherapy-induced Thrombocytopenia (NCT05236582) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-14 |
| A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients (NCT05641610) | Institute of Hematology & Blood Diseases Hospital, China | 2022-02-16 |
| A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia (NCT05214391) | Institute of Hematology & Blood Diseases Hospital, China | 2022-02-15 |
| Avatrombopag for Chemotherapy-induced Thrombocytopenia (NCT05218226) | Institute of Hematology & Blood Diseases Hospital, China | 2022-02-10 |
| Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia (NCT05199909) | Institute of Hematology & Blood Diseases Hospital, China | 2022-01-25 |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma (NCT05137886) | Institute of Hematology & Blood Diseases Hospital, China | 2022-01-01 |
| Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma (NCT05536700) | Institute of Hematology & Blood Diseases Hospital, China | 2021-12-31 |
| Safety and Tolerability of VGB-R04 in Patients With Haemophilia B (NCT05152732) | Institute of Hematology & Blood Diseases Hospital, China | 2021-12-28 |
| Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL (NCT05071482) | Institute of Hematology & Blood Diseases Hospital, China | 2021-09-16 |
| Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies (NCT04993885) | Institute of Hematology & Blood Diseases Hospital, China | 2021-09-01 |
| R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL (NCT04992377) | Institute of Hematology & Blood Diseases Hospital, China | 2021-08-30 |
| TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies (NCT04915482) | Institute of Hematology & Blood Diseases Hospital, China | 2021-06-06 |
| National Longitudinal Cohort of Hematological Diseases (NICHE) - CART (NCT06607289) | Institute of Hematology & Blood Diseases Hospital, China | 2021-06-01 |
| TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years (NCT04890041) | Institute of Hematology & Blood Diseases Hospital, China | 2021-05-30 |
| Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (NCT04854889) | Institute of Hematology & Blood Diseases Hospital, China | 2021-04-22 |
| Gene Therapy for Chinese Hemophilia A (NCT04728841) | Institute of Hematology & Blood Diseases Hospital, China | 2021-03-04 |
| Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients (NCT04725942) | Institute of Hematology & Blood Diseases Hospital, China | 2021-02-08 |
| CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma (NCT04690192) | Institute of Hematology & Blood Diseases Hospital, China | 2021-01-01 |
| Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. (NCT04688736) | Institute of Hematology & Blood Diseases Hospital, China | 2021-01-01 |
| Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients (NCT04696705) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-31 |
| Eltrombopag for Chemotherapy-induced Thrombocytopenia (NCT04600960) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-31 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (NCT04423367) | Institute of Hematology & Blood Diseases Hospital, China | 2020-09-13 |
| Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults (NCT04518475) | Institute of Hematology & Blood Diseases Hospital, China | 2020-08-10 |
| Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage (NCT04440267) | Institute of Hematology & Blood Diseases Hospital, China | 2020-07-08 |
| Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia (NCT04463953) | Institute of Hematology & Blood Diseases Hospital, China | 2020-06-01 |
| Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia (NCT04415008) | Institute of Hematology & Blood Diseases Hospital, China | 2020-06-01 |
| The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia (NCT04398459) | Institute of Hematology & Blood Diseases Hospital, China | 2020-05-01 |
| Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia (NCT04226950) | Institute of Hematology & Blood Diseases Hospital, China | 2020-01-10 |
| Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia (NCT04014166) | Institute of Hematology & Blood Diseases Hospital, China | 2019-11-21 |
| Gene Therapy for Chinese Hemophilia B (NCT04135300) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-16 |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (NCT04028440) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-01 |
| CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04034446) | Institute of Hematology & Blood Diseases Hospital, China | 2019-09-30 |
| A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04316624) | Institute of Hematology & Blood Diseases Hospital, China | 2019-09-29 |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT04322292) | Institute of Hematology & Blood Diseases Hospital, China | 2019-09-12 |
| A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (NCT03980002) | Institute of Hematology & Blood Diseases Hospital, China | 2019-05-15 |
| Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients (NCT03998059) | Institute of Hematology & Blood Diseases Hospital, China | 2019-01-23 |
| DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (NCT03837873) | Institute of Hematology & Blood Diseases Hospital, China | 2019-01-21 |
| to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection (NCT03664518) | Institute of Hematology & Blood Diseases Hospital, China | 2018-12-04 |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation (NCT03560908) | Institute of Hematology & Blood Diseases Hospital, China | 2018-07-01 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414) | Institute of Hematology & Blood Diseases Hospital, China | 2018-06-08 |
| a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients (NCT04008888) | Institute of Hematology & Blood Diseases Hospital, China | 2018-01-05 |
| Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (NCT03384277) | Institute of Hematology & Blood Diseases Hospital, China | 2017-12-29 |
| The Mutation Profile and Prognosis in AML With IDH1/2 Mutation (NCT07004816) | Institute of Hematology & Blood Diseases Hospital, China | 2017-12-21 |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma (NCT03029338) | Institute of Hematology & Blood Diseases Hospital, China | 2017-06-08 |
| Data Registry in Chinese Hemophilia A and B Patients (NCT07101224) | Institute of Hematology & Blood Diseases Hospital, China | 2017-05-07 |
| Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML (NCT03021330) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy of Decitabine in Clearance of MRD (NCT03021395) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia (NCT03031249) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy and Safety of Chidamide in CBF Leukemia (NCT03031262) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia (NCT02975687) | Institute of Hematology & Blood Diseases Hospital, China | 2016-11-01 |
| Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML (NCT02937662) | Institute of Hematology & Blood Diseases Hospital, China | 2016-10-01 |
| The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia (NCT03173612) | Institute of Hematology & Blood Diseases Hospital, China | 2016-08-01 |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (NCT02844361) | Institute of Hematology & Blood Diseases Hospital, China | 2016-05-01 |
| The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (NCT02844309) | Institute of Hematology & Blood Diseases Hospital, China | 2016-05-01 |
| The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (NCT02844322) | Institute of Hematology & Blood Diseases Hospital, China | 2016-05-01 |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL (NCT02858804) | Institute of Hematology & Blood Diseases Hospital, China | 2016-01-01 |
| Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (NCT02523976) | Institute of Hematology & Blood Diseases Hospital, China | 2015-08-01 |
| Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients (NCT02267993) | Institute of Hematology & Blood Diseases Hospital, China | 2014-10-01 |
| A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia (NCT02203396) | Institute of Hematology & Blood Diseases Hospital, China | 2014-08-01 |
| Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease (NCT02287831) | Institute of Hematology & Blood Diseases Hospital, China | 2014-02-01 |
| TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL (NCT04453345) | Institute of Hematology & Blood Diseases Hospital, China | 2013-05-20 |
| Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) (NCT01760096) | Institute of Hematology & Blood Diseases Hospital, China | 2013-01-01 |
| Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia (NCT01719692) | Institute of Hematology & Blood Diseases Hospital, China | 2012-10-01 |
| Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria (NCT01642979) | Institute of Hematology & Blood Diseases Hospital, China | 2012-07-01 |
| Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. (NCT01579110) | Institute of Hematology & Blood Diseases Hospital, China | 2012-04-01 |
| Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia (NCT03165851) | Institute of Hematology & Blood Diseases Hospital, China | 2005-04-10 |
| National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia (NCT07019038) | Institute of Hematology & Blood Diseases Hospital, China | 2001-01-01 |
| National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia (NCT07019766) | Institute of Hematology & Blood Diseases Hospital, China | 2000-01-01 |
| A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies (NCT04008524) | Institute of Hematology & Blood Diseases Hospital, China | |